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(EndocrinoZ.  Metab.  33):  El015-El021,  1996.-The  influ- 
ences  of  glucagon-like  peptide-I-(  7-36)  amide  (GLP-I;  15 
pmol  l  kg-l  l  min-l)  on  glucose  turnover  were  studied  in  freely 
moving  Wistar  rats.  In  fed  rats,  GLP-I  reduced  plasma 
glucose  (from  7.3  ?  0.2  to  5.6  ?  0.3  mmol/l;  P  =  0.017), 
increased  plasma  insulin  (from  20  5  3  to  89  t  11  mu/l;  P  = 
O.OOZ>, and  reduced  plasma  glucagon  (from  44  IT  1  to  35  t  2 
pg/ml;  P  =  0.009)  and  glucose  appearance  rate  (R,;  from  3.9  t 
0.2  to  1.7  t  0.7  pmol*min-  l  l  100  g-l  after  30  min;  P  =  0.049) 
without  affecting  glucose  disappearance  rate  (Rd).  The  glu- 
cose  clearance  rate  (MCR)  was  increased  (P  =  0.048).  In 
4%h-fasted  rats,  GLP-I  reduced  plasma  glucose  (from  5.0  t 
0.2  to  4.4  *  0.3  mmol/l;  P  =  0.035)  and  increased  plasma 
insulin  (from  4  t  1 to  25  t  10  mu/l;  P  =  0.042)  and  plasma 
glucagon  (from  43  _  +  3  to  61  IT  7 pg/ml;  P  =  0.046).  R,  and  Rd 
were  not  significantly  affected,  although  R,  was  lower  than  Rd 
after  15-30  min  (P  =  0.005)  and  MCR  was  increased  (P  = 
0.049).  Thus  GLP-I  reduces  R,  in  fed  rats  and  increases  MCR 
in  fed  and  fasted  rats.  The  reduced  R,  seems  mediated  by  an 
increased  insulin-to-glucagon  ratio;  the  increased  glucose 
clearance  seems  dependent  on  insulin  and  a peripheral  effect 
of GLP-I. 
the  peptide  increased  glucose utilization  during  a hyper- 
glycemic  hyperinsulinemic  clamp  in  type  1  diabetic 
patients  (12).  Furthermore,  GLP-I  might  also  reduce 
the  glucose levels  by  potentiating  the  insulin-indepen- 
dent  glucose  disposal,  as has  been  shown  in  fasted 
healthy  human  subjects  (5).  This  is in  agreement  with 
our  previous  observation 
circulating  glucose levels  in 
that 
mice 
the  peptide  reduced 
which  had  been given 
2,5-anhydro-D-mannitol,  a compound  known  to inhibit 
glycogenolysis,  gluconeogenesis,  and  insulin  secretion 
(4). Alternatively,  the  effects  described  above  might  be 
explained  by  an  inhibitory  action  of  GLP-I  on  hepatic 
glucose  delivery  through  a  potentiation  of  the  previ- 
ously  described  glucose-dependent  inhibition  of hepatic 
glucose delivery  (19). The  differing  results  indicate  that 
the  relative  contribution  to  the  glucose-lowering  effect 
of  GLP-I  by  reduction  of  hepatic  glucose  delivery  vs. 
stimulation  of  peripheral  glucose  disposal  is still  not 
established.  Neither  is it  known  whether  the  mecha- 
nism of the  glucose-lowering  effect  of GLP-I  is different 
under  fasting  and fed conditions. 
To  study  further  the  mechanism  of  the  glucose- 
lowering  effect  of GLP-I,  we  examined  the  influence  of 
the  peptide  on hepatic  glucose delivery  and  peripheral 
glucose disposal by  use of the  glucose tracer  technique 
in rats  under  both  fed and fasting  (48 h) conditions. 
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MATERIALS  AND  METHODS 
THE  TRUNCATED  AMIDATED  FORM  of  glucagon-like  pep- 
tide-1  (GLP-I)  is processed from  proglucagon  in  L  cells 
in  the  distal  portion  of the  gut  and  is released  into  the 
bloodstream  during  and after  food intake  (3, 6,  10, 22). 
GLP-I  has been shown to stimulate  insulin  secretion  in 
both  humans  and experimental  animals  (1, 5,  8, 9,  11, 
12,  15,  17, 18,  20,  26) and  is considered  an  important 
incretin  factor  (3,  6,  10, 22).  The  peptide  also inhibits 
glucagon  secretion  (9,  12,  23)  and  reduces  plasma 
glucose levels (4,21).  Because of this  unique  pattern  of 
effects,  the  peptide  has attracted  great  interest  as a 
potential  treatment  modality  in  type  2  diabetes  (12, 
20) 
The  mechanism  underlying  the  reduced  circulating 
glucose  levels  by  GLP-I  has not  been  established.  In 
overnight-fasted  human  subjects,  infusion  of  GLP-I 
reduces hepatic  glucose delivery,  which  most likely  is a 
consequence of increased  insulin  and  decreased  gluca- 
gon  secretion  (16).  In  addition,  GLP-I  increases  the 
metabolic  clearance  of glucose,  presumably  because  of 
increased  insulin  levels  (16).  There  is  also  evidence, 
however,  that  GLP-I  reduces circulating  glucose levels 
by  a  peripheral  insulin-independent  action,  because 
AnimaZs.  Male  Wistar  rats,  weighing  290-320  g  at  the 
beginning  of the  present  experiment,  were  used.  The  animals 
were  individually  housed  in  Plexiglas  cages  (25  X  25  X  30  cm) 
at  room  temperature  (20  t  2°C)  and  had  continuous  access  to 
food  (Hope  farm  chow)  and  water  unless  otherwise  stated. 
The  rats  were  maintained  on  a  12:12-h  light-dark  cycle 
(0700-1900  light),  and  they  were  handled  and  weighed  every 
day.  Under  halothane  anesthesia  and  3 wk  before  the  experi- 
ments,  all  rats  were  provided  with  a nonocclusive  catheter  in 
the  abdominal  artery  according  to  techniques  described  else- 
where  (29).  This  catheter  allows  frequent  arterial  blood 
sampling  in  freely  moving  undisturbed  rats.  For  venous 
infusion  of tritiated  glucose  and/or  GLP-I  solutions,  rats  were 
also  provided  with  a  silicon  catheter  that  was  inserted  in  the 
heart  via  the  right  jugular  vein  (28).  Before  experiments, 
catheters  were  filled  with  polyvinylpyrrolidone  (mol  wt  2,500). 
Patency  of the  aortic  and  venous  catheters  was  checked  every 
3 and  7  days,  respectively. 
Experimental  procedures.  All  experiments  were  performed 
in  the  light  period  between  1100  and  1400  in  the  home  cage  of 
the  animals.  Food  was  removed  from  the  cage  2 or  48  h  before 
the  start  of the  experiment.  One  hour  before  blood  sampling, 
venous  and  arterial  catheters  were  connected  to  polyethylene 
tubes  (length  0.4  m,  OD  1.25  mm,  ID  0.75  mm)  filled  with 
titrated  saline.  Forty-five  minutes  before  the  first  blood 
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sample,  a  priming  dose  of 2.1  uCi  D-[3-3H]glucose  (NET  331, 
New  England  Nuclear,  Boston,  MA),  followed  by  a  constant- 
rate  infusion  of  93  nCi/min,  was  delivered  intravenously. 
After  withdrawal  of each  blood  sample,  an  equal  amount  of 
titrated  blood  (10%)  was  given  to  avoid  diminution  of  the 
blood  volume.  Donor  blood  was  obtained  from  undisturbed 
donor  rats  with  permanent  heart  catheters.  In  the  intervals 
between  withdrawal  of each  blood  sample,  the  tip  of the  aortic 
catheter  was  filled  with  6%  titrated  saline  solution  as  an 
anticoagulant.  Arterial  blood  samples  of 0.6  ml  were  taken  for 
determination  of  plasma  concentrations  of  glucose,  insulin, 
glucagon,  and  GLP-I  and  to  determine  the  rate  of appearance 
(R,)  and  disappearance  (Rd)  of  glucose.  Before  the  start  of 
intravenous  infusion  of  synthetic  GLP-I  [proglucagon-(  78- 
107)  amide;  Peninsula  Europe,  Merseyside,  UK]  or  vehicle 
(1%  human  albumin  in  serum)  at  designated  time  (t)  0,  three 
baseline  blood  samples  were  taken  at  t  =  -30  min,  -  15  min, 
and  -30  s.  The  dosage  of  GLP-I  was  chosen  to  deliver  15 
pmol  l  min-1  l  kg-l.  Thi l  s  d ose  was  selected  on  the  basis  of  a 
previous  study  in  rats  in  which  a dose  of -125  pmol/kg  of the 
similar  peptide  GLP-I-(7-37)  was  administered  as  an  intra- 
venous  bolus  injection  in  rats  and  found  to  augment  glucose- 
stimulated  insulin  secretion  and  at  the  same  time  be  metabo- 
lized  within  8  min  (14).  During  infusion  of GLP-I  or  vehicle, 
blood  samples  were  taken  at t  =  15,30,45,60,  and  75  min. 
ChemicaZ  determinations.  Blood  samples  were  immedi- 
ately  transferred  to  chilled  (0’0  centrifuge  tubes  containing 
EDTA  (O.Ol%>,  heparin  (500  IU/ml),  and  aprotinin  (trypsin 
inhibitor,  500  kallikrein  inhibitor  units/ml)  and  were  centri- 
fuged  for  15  min  at  5,000  rpm  at  4°C.  The  supernatant  was 
stored  at  -70°C  until  analyzed.  Determination  of  plasma 
glucose  concentrations  was  enzymatically  performed  in  triple 
lo-u1  samples.  Rat-specific  plasma  immunoreactive  insulin 
and  glucagon  were  determined  by  means  of radioimmunoas- 
say  kits.  Guinea  pig  serum  (for  insulin  M8309  and  for 
glucagon  K5563,  both  from  Novo  Nordisk,  Bagsvaerd,  Den- 
mark)  served  as  antisera.  A  second  antibody  binding  to 
donkey  anti-rabbit  antibody-coated  cellulose  particles  (SAC- 
CEL  ASAC  1;  Immuno  Diagnostics,  UK)  was  performed  for 
glucagon  analysis.  Plasma  concentrations  of  GLP-I  were 
measured  with  a  radioimmunoassay  after  extraction  with 
ethanol,  as  previously  described  (24).  The  antiserum  used 
(code  no.  89390)  is  highly  specific  for  GLP-I  of  intestinal 
origin.  Analytic  procedures  for  [3H]glucose  were  performed  as 
previously  described  (30). 
CaZcuZations  and  statistics.  Glucose  R,  and  Rd  were  calcu- 
lated  using  Steele’s  equations  (27),  which  allow  determina- 
tions  in  steady-state  as  well  as  non-steady-state  conditions. 
The  volume  of distribution  in  which  rapid  changes  in  glucose 
concentration  and  specific  activity  of  [3H]glucose  take  place 
was  set  to  188  ml/kg  (25).  R,  and  Rd  values  in  Figs.  2,4,  and  5 
are  demonstrated  between  the  time  points  for  the  samples 
used  for  their  calculations.  For  example,  when  samples  taken 
at  t  =  15  and  t  =  30  min  were  used  for  the  calculation,  the  R, 
and  Rd  are  shown  at  t  =  22.5  min.  The  clearance  of glucose 
was  calculated  by  glucose  Rd  divided  by  plasma  glucose 
concentrations.  All  results  are  presented  as  means  t  SE.  For 
statistical  evaluation  of the  data,  Student’s  paired  and  un- 
paired  t-tests  were  used. 
RESULTS 
Fed  rats.  On the  experimental  day, the  ad libitum-fed 
rats  receiving  the  GLP-I  solution  (n  =  5)  and  vehicle 
(n  =  6)  weighed  357  -  +  8 and  353  *  5 g, respectively. 
Table  1 shows the  baseline  plasma  glucose, insulin,  and 
Table  1.  Baseline  levels ofplasma  insulin,  glucagon, 
glucose, and  GLP-I,  the glucose R,  and Rd, and  the 
MCR  in freely  fed and  48-h-fasted  rats 
Fed  Rats  Fasted  Rats 
(n  =  11)  (72 =  10)  P 
Insulin,  mU/l  23.0  +  1.6  3.9  +  1.1  <O.OOl 
Glucagon,  pg/ml  4621  4452  0.96  (NS) 
Glucose,  mmol/I  7.2  t  0.1  5.12  0.1  <O.OOl 
GLP-I,  pmol/l  18.5  +  1.7  12.6  2  1.3  0.013 
Glucose  R,,  umol  l  min-l  l 
100  g-i 
Glucose  Rd,  umol  l  rnin  l 
3.8  It  0.2  1.5  2  0.1  <O.OOl 
100  g-1  3.7  t  0.1  1.4  5  0.1  <O.OOl 
MCR,  ml  l  rnin  l  100  g-l  0.51  t  0.01  0.27  5  0.02  <O.OOl 
Values  are  means  +  SE.  GLP-I,  glucagon-like  peptide-I.  Glucose 
rates  of  appearance  (R,)  and  disappearance  (Rd)  and  the  glucose 
clearance  rate  (MCR)  were  calculated  after  30-45  min  of  infusion  of 
D-[3-3H]gIucose.  P  indicates  the  probability  level  of  random  difference 
between  the  2  groups;  NS  indicates  no  significant  difference  (P  > 
0.050). 
glucagon  levels  as  well  as  the  Ray the  Rd,  and  the 
clearance  rate  of glucose. Fig.  1 shows the plasma  levels 
of  glucose,  insulin,  and  glucagon  before  and  during 
infusion  of  GLP-I  (n  =  5) or  vehicle  (n  =  6) in  the  fed 
rats.  Intravenous  infusion  of GLP-I  reduced  the  plasma 
glucose levels  from  7.3  -  +  0 2 to  5.6  +  0.3 mmol/l  at  30  . 
min,  i.e.,  by  1.7  t  0.5  mmol/l  (P  =  i.017).  Thereafter 
the  glucose levels  gradually  returned  toward  the  prein- 
fusion  levels.  Furthermore,  GLP-I  markedly,  although 
transiently,  increased  plasma insulin  levels from 20 IT 3 
to 89 ?  11 mu/l  after  15 min  of infusion,  i.e.,  by  69 t  10 
mu/l  (P  =  0.002).  After  15 min  of infusion,  the  plasma 
insulin  levels  returned  to  baseline  despite  the  ongoing 
GLP-I  infusion.  The  plasma  insulin  levels did  not  drop 
below  those  in  the  controls,  even  though  the  plasma 
glucose levels were  lower.  Plasma  glucagon  levels were 
constantly  reduced  during  the  GLP-I  infusion,  being 
44  t  1 pg/ml  before  GLP-I  infusion  and  35  t  2 pg/ml 
after  45  min  of  peptide  infusion  (P  =  0.009).  After  15 
min  of  GLP-I  infusion,  the  plasma  insulin-to-plasma 
glucagon  ratio  was  2.5  ?  0.4  uU/pg,  whereas  the 
corresponding  ratio  in saline-infused  controls was 0.39 t 
0.03  pu/pg  (P  =  0.009).  In  the  vehicle-infused  control 
rats,  no  significant  changes were  observed  in  plasma 
glucose, insulin,  or glucagon  levels. 
Figure  2 shows the  R,  and  Rd of glucose  during  the 
infusion  of  GLP-I  and  vehicle  in  fed  rats.  R,  was 
significantly  reduced  during  the  first  30 min  of GLP-I 
infusion,  because it  fell from  3.9  t  0.2 umolmin-la  100 
g-l  before  the  start  of  GLP-I  infusion  to  1.7  t  0.7 
umol=minl.  100  g-l  during  30  min  of  infusion  (P  = 
0.049).  After  30  min,  R,  returned  to  control  levels 
despite  the  ongoing  infusion  of  GLP-I  and  the  con- 
stantly  reduced  plasma  glucagon  levels.  In  contrast,  Rd 
was not  significantly  affected  by  GLP-I.  It  was 3.6 t  0.2 
umolmin-l  l  100 g-l  before  and  3.1  t  0.2 pmol*minl. 
100 g-l  after  30 min  of infusion  [not  significant  (NS)]. 
At  the  same time,  however,  plasma glucose values were 
lowered  by  GLP-I  (see  Fig.  1).  Hence  the  glucose 
clearance  rate,  i.e.,  glucose Rd-to-plasma  glucose ratio, GLP-I  AND  GLUCOSE  TURNOVER  El017 
Thereafter,  plasma  glucose  levels  gradually  returned  to 
baseline  values.  Similarly  to  the  fed  rats,  GLP-I  in- 
duced  a  transient  increase  in  plasma  insulin  levels  in 
the  fasted  rats,  from  4  5  1 to  25  5  10 mu/l  after  15 min 
of  infusion,  i.e.,  by  21  t  8 mu/l  (P  =  0.042).  Thereafter, 
the  insulin  values  returned  to  the  low  baseline  levels 
-,  , 
despite  the  ongoing  GLP-I  infusion.  As  in  the  fed  rats, 
plasma  insulin  levels  never  dropped  below  control 
values,  yet  plasma  glucose  levels  were  lower  in  GLP-I- 
-30  -15  0  15  30  45  60  75  than  in  vehicle-infused  rats.  In  contrast  to  what  was 
observed  in  the  fed  rats,  plasma  glucagon  levels  tran- 
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Fig.  1.  Plasma  glucose  (A),  insulin  (B),  and  glucagon  concentrations 
(C)  in  freely  fed  rats  intravenously  infused  with  glucagon-like 
peptide-  (GLP-I;  n  =  5;  15  pmol  kg-l*rnin-l;  0)  or  vehicle  (n  =  6;  0). 
During  experiments,  all  rats  were  infused  with  D-[3-3H]glucose  from 
t  =  -75  min,  i.e.,  45  min  before  the  first  blood  sample.  The  infusion  of 
GLP-I  or  vehicle  started  at  time  0.  Values  are  means  +  SE. 
was  significantly  increased  by  GLP-I,  because  it  was 
0.56  t  0.04 ml~min-l~lOO  g-l  after  30 min  of  peptide 
infusion  compared  with  0.43  ?  0.04  ml*minl*  100 g-l 
after  infusion  of  vehicle  (P  =  0.048).  Infusion  of  the 
vehicle  did  not  significantly  alter  R,,  Rd, or  the  clear- 
ance rate  of glucose. 
Fasted  rats.  On the experimental  day, the  4%h-fasted 
rats  receiving  the  GLP-I  solution  (n  =  5)  and  vehicle 
(n  =  5) weighed  320  2  7 and  320  t  4  g, respectively. 
During  the  fasting  period,  rats  lost  on average  49 t  2 g 
of  body  weight.  Table  1  shows  the  baseline  plasma 
glucose,  insulin,  and glucagon  levels  as well  as the  R,, 
the  Rd, and  the  clearance  rate  of  glucose  in  the  48-h- 
fasted  rats.  Figure  3 shows the  plasma glucose, insulin, 
and glucagon  levels in the  48-h-fasted  rats  infused  with 
GLP-I  (n  =  5) or vehicle  (n  =  5). As in  the  fed  rats,  the 
intravenous  infusion  of  GLP-I  reduced  the  plasma 
glucose  levels  also  in  the  fasted  rats,  from  5.0  t  0.2 
mmol/l  before  the  infusion  to  4.4  t  0.3 mmol/l  after  30 
min  of  infusion,  i.e.,  by  0.6  t  0.2  mmol/l  (P  =  0.035). 
siently  increased  during  the  GLP-I  infusion  in  the 
48-h-fasted  rats,  from  43  t  3 to  61  ?  7 pg/ml,  i.e.,  by 
18 5  6 pg/ml  after  30 min  of infusion  (P  =  0.046).  The 
peak  glucagon  values  coincided  with  the  nadir  glucose 
value;  thereafter  glucagon  levels  returned  to  preinfu- 
sion values.  After  15 min  of GLP-I  infusion,  the  plasma 
insulin-to-plasma  glucagon  ratio  was 0.49  t  0.18  uU/ 
pg, whereas  the  corresponding  ratio  in  vehicle-infused 
controls  was 0.06  t  0.02  uU/pg  (P  =  0.041).  However, 
after  30 min  of infusion,  the  plasma  insulin-to-plasma 
glucagon  ratio  had returned  to 0.11 t  0.04 uU/pg  in the 
GLP-I-infused  animals  vs.  0.06  t  0.02  uU/pg  in  the 
controls  (NS).  In  the  vehicle-infused  control  rats,  no 
significant  changes were  observed  in  plasma  glucose, 
insulin,  or glucagon  levels. 
Figure  4 shows the  glucose R,  and Rd during  infusion 
of  GLP-I  and  vehicle  in  the  48-h-fasted  rats.  Neither 
the  glucose  R,  nor  the  glucose  Rd  was  significantly 
affected  by  GLP-I.  R,  was significantly  lower  than  Rd at 
the  interval  of 15-30  min  after  start  of GLP-I  infusion 
(0.83  5  0.15  vs.  1.63  2  0.15  umol*min+  100 g-l;  P  = 
-30  -15  0  15  30  45  60 
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Fig.  2.  Glucose  rates  of  appearance  (A)  and  disappearance  (B)  in 
freely  fed  rats  intravenously  infused  with  GLP-I  (n  =  5;  15  pmol 
kg-l  *mini;  0)  or  vehicle  (n  =  5;  0).  Infusions  are  as  described  in 
Fig.  1.  Values  (means  +  SE)  are  calculated  from  changes  between  2 
time  points  and  are  reported  here  between  those  2  time  points. El018  GLP-I  AND  GLUCOSE  TURNOVER 
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Fig.  3.  Plasma  glucose  (A), insulin  (B),  and  glucagon  concentrations 
(C)  in  rats  fasted  for  48  h  and  infused  intravenously  with  GLP-I  (n  = 
5;  15  pmol  l  kg-l  l  min  -‘;  0)  or  vehicle  (n  =  5;  0).  Infusions  are  as 
described  in  Fig.  1.  Values  are  means  +  SE. 
0.005;  Fig.  5), which  was at the  time  point  when  plasma 
glucose values  were  lowered  by  GLP-I  (see Fig.  3). The 
glucose  clearance  rate,  i.e.,  glucose  Rd-to-plasma  glu- 
cose ratio,  was  significantly  higher  after  30  min  of 
infusion  with  GLP-I,  0.38  t  0.04  mlmin-lo  100  g-l, 
than  during  infusion  of  vehicle,  0.26  ?  0.03 
ml.  minl  l  100 g-l  (P  =  0.049).  Vehicle  infusion  did  not 
significantly  alter  glucose  R,,  glucose Rd, or  the  clear- 
ance of glucose in the  fasted  rats. 
Plasma  GLP-I  levels.  Table  1 and Fig.  6 show plasma 
GLP-I  levels  before  and  during  infusion  of  GLP-I  and 
vehicle  in  freely  fed  and  48-h-fasted  rats.  The  baseline 
plasma  GLP-I  levels  were  significantly  higher  in  fed 
rats  (18 5 +  1.7 pmol/l)  than  in 48-h-fasted  rats  (12.6  ? 
1.3 pmoi/l;-P  =  0.013).  The  plasma  GLP-I  levels  in  fed 
and fasted  rats  during  GLP-I  infusions  were  not  signifi- 
cantly  different. 
DISCUSSION 
In  the  present  study,  we found  that  GLP-I  transiently 
reduces  the  R,  of  glucose  by  31%  in  freely  fed  rats, 
without  affecting  the  Rd of  glucose.  This  resulted  in  a 
transient  reduction  of  plasma  glucose  levels  by  1.7 
mmol/l  (Fig.  1). The  clearance  rate  of  glucose,  i.e.,  the 
I 
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Fig.  4.  Glucose  rates  of  appearance  (A) and  disappearance  (B)  in  rats 
fasted  for  48  h  and  infused  intravenously  with  GLP-I  (n  =  5;  15 
pmol  l  kg-l.  min  -l;  0)  or  vehicle  (n  =  5;  0).  Infusions  are  as  described 
in  Fig.  1. Values  (means  +  SE)  are  calculated  from  changes  between  2 
time  points  and  are  reported  here  between  those  2  time  points. 
rate  by  which  each  circulating  millimole  of glucose  is 
cleared,  was increased  during  GLP-I  infusion,  because 
glucose  Rd remained  unaffected  whereas  plasma  glu- 
cose levels  decreased.  Furthermore,  the  study  demon- 
strates  that  the  pepti .de increases  plasma  insulin  and 
reduces plasma  glucagon  in  fed rats.  We interpret  these 
findings  to  indicate  that  GLP-I  in  fed  rats  markedly 
increases  the  insulin-to-glucagon  ratio,  which  reduces 
hepatic  glucose  output.  The  insulinotropic  action  of 
GLP-I  vanished  after  30 min,  and,  as a result,  the  low 
glucose 
despite 
R, increased  again  toward  control  values.  Thus, 
levels of plasma  glucagon  constantly  remaining 
low,  GLP-I  only  transiently  influenced  glucose  R,.  At 
the  same time,  GLP-I  increases  the  efficacy  of periph- 
eral glucose uptake,  which  might  be an effect  mediated 
by  insulin  or directly  stimulated  by  GLP-I. 
Our  results  confirm  the  previously  reported  study  in 
overnight-fasted  humans,  in  which  GLP-I  reduced  the 
01’  ”  ”  ”  ’ 
-30  -15  0  15  30  45  60  75 
Time  (minutes) 
Fig.  5.  Glucose  rates  of  appearance  (glucose  R,;  0)  and  disappear- 
ance  (glucose  Rd;  0)  before  and  during  intravenous  infusion  of  GLP-I 
(15  pmol*kg-l+min-l)  in  4%h-fasted  rats.  Values  (means  5  SE)  are 
calculated  from  changes  between  2  time  points  and  are  reported  here 
between  those  2  time  points.  R,  and  Rd  were  significantly  different  at 
t  =  22.5  min  (P = 0.005). GLP-I  AND  GLUCOSE  TURNOVER  El019 
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Fig.  6.  Plasma  GLP-I  concentrations  before  and  during  intravenous 
infusion  of  GLP-I  (15  pmol  l  kg-l  l  min-  l;  0)  or  vehicle  (0)  in  freely  fed 
rats  (A)  and  in  rats  fasted  for  48  h  (B).  Infusions  started  at  time  0. 
Values  are  means  +  SE  for  5-6  rats  in  each  group. 
R,  and  lowered  circulating  glucose  without  affecting 
the  Rd  (16).  Our  result,  that  GLP-I  increased  the 
glucose  clearance,  also  confirms  the  studies  by  Gutniak 
et  al.  (12),  showing  that  GLP-I  increases  insulin  sensi- 
tivity  during  a hyperglycemic  clamp  in  type  1 diabetics, 
and  by  D’Alessio  et  al.  (5),  showing  that  GLP-I  potenti- 
ates  insulin-independent  glucose  disposal.  Finally,  the 
results  corroborate  our  recent  studies  in  mice,  demon- 
strating  that  GLP-I  lowers  plasma  glucose  both  in 
insulin-deficient  alloxan-diabetic  mice  (2)  and  after 
inhibition  of liver  gluconeogenesis,  liver  glycogenolysis, 
and  insulin  secretion  from  B  cells  by  2,5-anhydro-D- 
mannitol  in  normal  mice  (4).  Therefore,  we  conclude 
that  GLP-I  reduces  glucose  levels  by  a  hepatic,  but 
possibly  also  by  a  peripheral  effect,  the  hepatic  effect 
being  the  result  of  an  increased  insulin-to-glucagon 
ratio. 
In  the  present  study,  infusion  of  GLP-I  led  to  in- 
creased  plasma  insulin  levels  and  reduced  plasma 
glucose  levels  in  both  the  fed  and  the  fasted  state.  In 
the  fasted  rats,  no  significant  differences  were  observed 
in  absolute  values  of  R,  or  Rd  during  the  intravenous 
infusion  with  GLP-I.  However,  at  E-30  min  after  start 
of  the  infusion,  Rd  was  significantly  higher  than  R,, 
which  would  suggest  a  change  in  the  R,-Rd  balance, 
indicative  of  a  stimulated  clearance  of  glucose.  The 
main  mechanism  underlying  the  glucose-reducing  ef- 
fect  of  GLP-I  under  fasting  conditions  is  therefore 
probably  a  stimulated  clearance  of  glucose.  The  fact 
that  glucose  R,  was  not  altered  during  GLP-I  infusion 
in  fasted  rats  is  probably  due  to  the  fact  that  the 
increase  in  the  ratio  of  plasma  insulin  to  plasma 
glucagon  was  low  in  these  rats.  During  GLP-I  infusion 
in  fasted  rats,  plasma  glucagon  levels  were  not  re- 
duced.  This  was  not  expected,  because  GLP-I  has 
previously  been  shown  to  inhibit  glucagon  secretion  in 
humans  (12)  as  well  as  in  experimental  animals,  includ- 
ing  rodents  (9,  23).  It  is  likely  that  the  hypoglycemic 
action  of  GLP-I  under  the  48-h-fasting  condition  led  to 
an  increased  activation  of  the  sympathoadrenal  system 
(13),  which  m ay  h ave  counteracted  the  direct  inhibitory 
action  of  GLP-I  on  glucagon  secretion.  Taken  together, 
the  results  of  the  present  study  indicate  that  the 
glucose-lowering  effect  of  GLP-I  in  fasted  rats  is  medi- 
ated  by  stimulated  glucose  clearance  rate  and  that  the 
reduced  R,,  which  is  seen  only  under  fed  conditions,  is 
not  directly  mediated  by  GLP-I.  Rather,  the  reduced  R, 
seems  to  be  mediated  by  the  increased  insulin-to- 
glucagon  ratio  in  plasma,  which  was  markedly  in- 
creased  by  GLP-I  under  fed  conditions  but  only  mildly 
increased  during  fasting  conditions.  It  cannot  be  ex- 
cluded,  however,  that  GLP-I  in  addition  to its  effects  via 
pancreatic  hormone  secretion  also  directly  reduces  R, 
and  that  this  effect  was  simply  counteracted  by  the 
rising  plasma  glucagon  levels  due  to  hypoglycemia 
under  fasting  conditions.  Therefore  more  direct  studies 
of  the  effects  on  GLP-I  on  liver  cell  glucose  metabolism 
are  required. 
Insulin  secretion  was  clearly  and  markedly  stimu- 
lated  by  GLP-I,  although  this  effect  was  more  pro- 
nounced  under  fed  than  under  fasted  conditions.  This 
could  not  be  attributed  to  differences  in  concentrations 
of  GLP-I  in  the  circulation,  because  the  infusion  of 
GLP-I  led  to  similar  levels  of  plasma  GLP-I  in  fed  and 
fasted  rats.  Thus  this  observation  may  reinforce  the 
idea  that  the  insulinotropic  action  of  GLP-I  is  glucose 
dependent  (3,6,  10,21).  In  particular,  a recent  study  in 
the  mouse  showed  a more  marked  insulinotropic  action 
of  GLP-I  under  fed  conditions  than  during  fasting  (1). 
The  finding  in  the  present  study,  that  the  increased 
plasma  insulin  levels  returned  to  preinfusion  values 
already  during  the  ongoing  infusion  of the  peptide,  has 
previously  been  demonstrated  in  humans  as  well  (21). 
This  phenomenon  might  be  explained  by  the  gradual 
lowering  of  plasma  glucose  levels,  which  weakens  the 
insulin  secretory  action  of  the  peptide.  However,  be- 
cause  the  plasma  glucose  levels,  at  least  under  fed 
conditions,  were  still  above  levels  required  for  the 
insulinotropic  action  of  GLP-I,  other  explanations  are 
also  possible.  For  example,  it  may  be  speculated  that 
GLP-I  has  induced  a  desensitization  on  the  B  cells 
during  its  infusion,  as  has  been  suggested  from  studies 
on  the  effect  of  GLP-I  on  adenosine  3’,5’-cyclic  mono- 
phosphate  production  in  cultured  cell  lines  transfected 
to  express  the  GLP-I  receptor  (31).  Whether  desensiti- 
zation  occurs  of  GLP-I  receptors  located  on  B  cells  in 
vivo  remains  to  be studied. 
A  question  that  still  remains  to  be  solved  is  whether 
the  effects  on  glucose  turnover  observed  during  GLP-I 
infusion,  i.e.,  reduced  R,  in  fed  rats  and  increased 
glucose  clearance  rate  in  both  fed  and  fasted  animals, 
are  solely  mediated  by  the  increased  insulin-to-gluca- 
gon  ratio  or  whether  a  direct  action  of  GLP-I  contrib- 
utes  to  these  phenomena.  The  increased  glucose  clear- El020  GLP-I  AND  GLUCOSE  TURNOVER 
ante  induced  by  GLP-I  could  be  at  least  partially 
mediated  by  a  direct  action  of  the  peptide,  because  it 
was  of the  same  magnitude  in  fed  and  fasted  conditions, 
yet  the  insulinotropic  action  of the  peptide  was  weaker 
under  fasted  conditions.  Furthermore,  because  glucose 
Rd  was  unaffected  during  GLP-I  infusion,  an  insulin- 
independent  action  seems  to  contribute  to  the  in- 
creased  glucose  clearance.  However,  the  exact  mecha- 
nism  underlying  the  increased  glucose  clearance  during 
GLP-I  infusion  remains  to  be established. 
In  conclusion,  we  have  demonstrated  that  the  mecha- 
nism  of  the  plasma  glucose-reducing  effect  of  GLP-I  in 
the  rat  is  dependent  on  the  nutritional  status.  Thus,  in 
the  freely  fed  state,  the  peptide  reduces  plasma  glucose 
by  reducing  hepatic  glucose  delivery  and  increasing  the 
clearance  rate  of  glucose,  whereas,  under  fasting  condi- 
tions,  the  glucose-lowering  effect  of  GLP-I  is  mediated 
mainly  by  increasing  the  glucose  clearance  rate.  Fur- 
thermore,  our  study  presents  evidence  that  the  reduced 
glucose  R,  induced  by  GLP-I  is  secondary  to  increased 
insulin  and  reduced  glucagon  secretion,  whereas  the 
stimul 
seems 
.ation  of  the  increased 
to  be  at  least  partial 
clearance  rate  of  glucose 
ly  secondary  to  a  direct 
peripheral  effect  of GLP-I.  Because  diabetes  is  accompa- 
nied  by  inappropriately  el  .evated  hepati  .c glucose  produc- 
tion  and  reduced  glucose  clearance  (7),  the  inhibition  of 
hepatic  glucose  output  and  the  stimulation  of  the 
peripheral  glucose  uptake  by  GLP-I  9  together  with  its 
effects  to  stimulate  insulin  secretion  and  inhibit  gluca- 
gon  secretion,  reinforce  the  need  for  further  studies  to 
explore  the  use  of this 
treatment  of  diabetes. 
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